Blueprint Medicines Q1 2023 Earnings Report
Key Takeaways
Blueprint Medicines reported strong AYVAKIT revenue growth and progress in expanding its impact and transforming outcomes for patients. The company achieved $39.1 million in AYVAKIT/AYVAKYT net product revenues and $63.3 million in total revenues in Q1 2023. They are raising 2023 AYVAKIT net product revenue guidance to $135 million to $145 million for advanced SM and GIST.
Achieved $39.1 million in AYVAKIT/AYVAKYT net product revenues in Q1 2023.
Total revenues reached $63.3 million in Q1 2023.
Raised 2023 AYVAKIT net product revenue guidance to $135 million to $145 million.
FDA target action date for AYVAKIT supplemental new drug application for indolent SM is May 22, 2023.
Blueprint Medicines
Blueprint Medicines
Forward Guidance
Blueprint Medicines anticipates approximately $135 million to $145 million in AYVAKIT net product revenues for advanced SM and GIST in 2023, and $40 million to $50 million in collaboration revenues from existing collaborations in 2023. This guidance excludes revenue from the anticipated AYVAKIT indication expansion in ISM in mid-2023.